Literature DB >> 10438876

Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase.

D Hartigan-O'Connor1, A Amalfitano, J S Chamberlain.   

Abstract

Production of gutted, or helper-dependent, adenovirus vectors by current methods is inefficient. Typically, a plasmid form of the gutted genome is transfected with helper viral DNA into 293 cells; the resulting lysate is serially passaged to increase the titer of gutted virions. Inefficient production of gutted virus particles after cotransfection is likely due to suboptimal association of replication factors with the abnormal origins found in these plasmid substrates. To test this hypothesis, we explored whether gutted virus production would be facilitated by transfection into cells expressing various viral replication factors. We observed that C7 cells, coexpressing adenoviral DNA polymerase and preterminal protein, converted plasmid DNA into replicating virus approximately 50 times more efficiently than did 293 cells. This property of C7 cells can be used to greatly increase the efficiency of gutted virus production after cotransfection of gutted and helper viral DNA. These cells should also be useful for generation of recombinant adenovirus from any plasmid-based precursor.

Mesh:

Substances:

Year:  1999        PMID: 10438876      PMCID: PMC104313     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Protein-protein interactions between adenovirus DNA polymerase and nuclear factor I mediate formation of the DNA replication preinitiation complex.

Authors:  M Chen; N Mermod; M S Horwitz
Journal:  J Biol Chem       Date:  1990-10-25       Impact factor: 5.157

2.  Transcription factors NFI and NFIII/oct-1 function independently, employing different mechanisms to enhance adenovirus DNA replication.

Authors:  Y M Mul; C P Verrijzer; P C van der Vliet
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

3.  A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase.

Authors:  S Kochanek; P R Clemens; K Mitani; H H Chen; S Chan; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

4.  Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors.

Authors:  A Amalfitano; C R Begy; J S Chamberlain
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

5.  The adenovirus terminal protein influences binding of replication proteins and changes the origin structure.

Authors:  R Pronk; P C van der Vliet
Journal:  Nucleic Acids Res       Date:  1993-05-25       Impact factor: 16.971

6.  Interactions between the adenovirus type 2 DNA polymerase and the DNA binding domain of nuclear factor I.

Authors:  J Bosher; E C Robinson; R T Hay
Journal:  New Biol       Date:  1990-12

7.  Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase.

Authors:  F W Van Ginkel; C Liu; J W Simecka; J Y Dong; T Greenway; R A Frizzell; H Kiyono; J R McGhee; D W Pascual
Journal:  Hum Gene Ther       Date:  1995-07       Impact factor: 5.695

8.  Adenovirus DNA polymerase is a phosphoprotein.

Authors:  M Ramachandra; R Nakano; P M Mohan; A B Rawitch; R Padmanabhan
Journal:  J Biol Chem       Date:  1993-01-05       Impact factor: 5.157

9.  Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs.

Authors:  Y Yang; Q Su; J M Wilson
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  Nuclear factor I enhances adenovirus DNA replication by increasing the stability of a preinitiation complex.

Authors:  Y M Mul; P C Van der Vliet
Journal:  EMBO J       Date:  1992-02       Impact factor: 11.598

View more
  10 in total

1.  Characterization of a permissive epitope insertion site in adenovirus hexon.

Authors:  Michael J McConnell; Xavier Danthinne; Michael J Imperiale
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  A rapid protocol for construction and production of high-capacity adenoviral vectors.

Authors:  Lorenz Jager; Martin A Hausl; Christina Rauschhuber; Nicola M Wolf; Mark A Kay; Anja Ehrhardt
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

3.  Impact of adenovirus life cycle progression on the generation of canine helper-dependent vectors.

Authors:  P Fernandes; D Simão; M R Guerreiro; E J Kremer; A S Coroadinha; P M Alves
Journal:  Gene Ther       Date:  2014-10-23       Impact factor: 5.250

4.  Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4.

Authors:  Michael J McConnell; Philip C Hanna; Michael J Imperiale
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

Review 5.  Gene therapy approaches for bone regeneration.

Authors:  Renny T Franceschi; Shuying Yang; R Bruce Rutherford; Paul H Krebsbach; Ming Zhao; Dian Wang
Journal:  Cells Tissues Organs       Date:  2004       Impact factor: 2.481

6.  Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin.

Authors:  Christiana DelloRusso; Jeannine M Scott; Dennis Hartigan-O'Connor; Giovanni Salvatori; Catherine Barjot; Ann S Robinson; Robert W Crawford; Susan V Brooks; Jeffrey S Chamberlain
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

7.  Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer.

Authors:  Joseph P Balint; Elizabeth S Gabitzsch; Adrian Rice; Yvette Latchman; Younong Xu; Gerald L Messerschmidt; Arvind Chaudhry; Michael A Morse; Frank R Jones
Journal:  Cancer Immunol Immunother       Date:  2015-05-09       Impact factor: 6.968

Review 8.  Viral vector platforms within the gene therapy landscape.

Authors:  Jote T Bulcha; Yi Wang; Hong Ma; Phillip W L Tai; Guangping Gao
Journal:  Signal Transduct Target Ther       Date:  2021-02-08

Review 9.  Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses.

Authors:  Mohammad Shoushtari; Farzin Roohvand; Mostafa Salehi-Vaziri; Arash Arashkia; Hasan Bakhshi; Kayhan Azadmanesh
Journal:  Hum Vaccin Immunother       Date:  2022-06-17       Impact factor: 4.526

Review 10.  Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties.

Authors:  Coralie F Daussy; Noémie Pied; Harald Wodrich
Journal:  Viruses       Date:  2021-06-24       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.